Q-omics provides the consensus-scored LY6G6F profile across patient tissues and cancer cell-line models. LY6G6F expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LY6G6F is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LY6G6F RNA expression shows 8,908 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where LY6G6F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6G6F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6G6F survival associations across molecular data types. LY6G6F RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6G6F RNA expression–survival associations across cancer types. High LY6G6F expression shows unfavorable associations in COAD and READ, but favorable associations in HNSC, CESC, LUSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for LY6G6F RNA expression.
This table summarizes LY6G6F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LY6G6F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6G6F shows lower tumor expression in LUSC, LUAD, THCA and KICH and higher tumor expression in COAD and READ. The COAD box plot shows higher LY6G6F RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with LY6G6F in patient tissues and cancer cell lines. In patient samples, LY6G6F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6G6F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
